Clinical trials: Dementia, Frontotemporal
Alzheimer's Disease, Progressive Primary Aphasia
tDCS Effect on Cognitive Functions From Patients With Alzheimer's Disease or Progressive Primary Aphasia
The purpose of this study is to evaluate the effect of 10 sessions of anodal transcranial Direct Current Stimulation (tDCS - 1 mA) applied to left Cortex DorsoLateral PreFrontal (CDLPF) of Alzheimer's or Primary Progressive…
- Conditions
- Alzheimer's Disease, Progressive Primary Aphasia, Early or Mild State
- Trial name
- ALSTICO (NCT02873546)
- Testing
- transcranial Direct Current Stimulation (tDCS)
- Where
- 3 sites in France
- Volunteers
- 52 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Frontotemporal Dementia, Deep Brain Stimulation
Subgenual Cingulate Deep Brain STIMulation for Apathetic Behavioral Variant FRONtotemporal Dementia
Frontotemporal dementia (FTD), the most common dementia in individuals younger than 60 years of age, has no disease-modifying treatment.
- Trial name
- FRONSTIM (NCT05699330)
- Testing
- Bilateral subgenual cingulate deep brain stimulation (SGC DBS)
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- University Health Network, Toronto
Frontotemporal Lobar Degeneration (FTLD)
Single-centre Descriptive Study of Taste in Frontotemporal Lobar Degeneration Through the Analysis of Taste Evoked Potentials
The FRONTAL-PEG study focuses on taste perception in frontotemporal lobar degeneration (FTLD). This neurodegenerative disease, characterised by progressive loss of nerve cells, is the second leading cause of dementia after…
- Trial name
- FRONTAL-PEG (NCT07110207)
- Testing
- Blood test, Interrogation of the subject, Cognitive assessment
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Amyotrophic Lateral Sclerosis, Alzheimer's Disease
Advances in Telephone-based Cognitive Screening Procedures
1. Background Cognitive screening procedures via performance-based tests represent an essential, albeit preliminary, element within the diagnostic and interventional process as addressed to patients with chronic neurological…
- Conditions
- Amyotrophic Lateral Sclerosis, Alzheimer's Disease, Lewy Body Dementia, Frontotemporal Degeneration
- Trial name
- TBCS (NCT06337578)
- Testing
- Telephone-based neuropsychological assessment - ALS, Telephone-based neuropsychological assessment - AD, LBD, FTD and CVD, Telephone-based and in-person cognitive screening - NIs
- Where
- Italy
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Istituto Auxologico Italiano
Frontotemporal Dementia, Dementia
Dopaminergic Therapy for Frontotemporal Dementia Patients
This is a phase IIa 24-week randomized, double-blind, placebo-controlled study. The study is designed to evaluate the efficacy and safety of Rotigotine (RTG) transdermal administration at the dosage of 4 mg or 6 mg per day versus…
- Conditions
- Frontotemporal Dementia, Dementia, Aphasia, Primary Progressive, Pick Disease of the Brain
- Trial name
- NCT04937452
- Testing
- Rotigotine 4Mg/24Hrs Patch, Rotigotine 6Mg/24Hrs Patch
- Where
- 3 sites in Italy
- Volunteers
- 75 people
- Sponsor
- I.R.C.C.S. Fondazione Santa Lucia
Primary Progressive Aphasia
Communication Bridge 3 Study
This study will use a randomized controlled trial design to evaluate the effect of two evidence-based treatments for adults with mild-moderate Primary Progressive Aphasia (PPA).
- Trial name
- CB3 (NCT06191198)
- Testing
- Communication Bridge™, Evidence-Based Impairment Focused
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Chicago
Adrenoleukodystrophy, Batten Disease
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
The primary objective of the study is to determine the safety and feasibility of intrathecal administration of DUOC-01 in patients who are undergoing standard treatment with umbilical cord blood transplant (UCBT) for inborn…
- Conditions
- Adrenoleukodystrophy, Batten Disease, Mucopolysaccharidosis II, Leukodystrophy, Globoid Cell
- Trial name
- DUOC-01 (NCT02254863)
- Testing
- DUOC-01
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Joanne Kurtzberg, MD
Niemann-Pick Disease, Type C
Safety and Tolerability Study of VTS-270 in Pediatric Participants With Niemann-Pick Type C (NPC) Disease
This is a Phase-2, multicenter, multiple dose, open-label, 2-part evaluation study which will primarily assess the safety and tolerability of VTS-270 (2-hydroxypropyl beta-cyclodextrin [HP-β-CD]) in pediatric participants with…
- Trial name
- NCT03687476
- Testing
- VTS-270
- Sponsor
- Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
TRIAL READY (Clinical Trial Readiness)
This study, being conducted under the auspice of the CReATe Consortium, will enroll patients with ALS and related disorders as well as healthy controls, with the goal of facilitating clinical validation of leading…
- Conditions
- Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, ALS-Frontotemporal Dementia, Primary Lateral Sclerosis
- Trial name
- NCT03912987
- Where
- 3 sites in United States
- Volunteers
- 610 people, healthy volunteers welcome
- Sponsor
- University of Miami
Alzheimer Disease, Dementia With Lewy Bodies
Neurological Soft Signs in Neurodegenerative Dementias
The goal of this observational study is to investigate the prevalence of Neurological Soft Signs (NSS) in various categories of dementia patients compared to matched controls.
- Conditions
- Alzheimer Disease, Dementia With Lewy Bodies, Frontotemporal Dementia, Corticobasal Degeneration
- Trial name
- DemeNSS (NCT06354933)
- Testing
- Neurological Soft Signs
- Where
- Italy
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- University of Milano Bicocca
Frontotemporal Lobar Degeneration
Identification of New FTLD Genes
The major objective of the project is to map/identify new loci/genes, by a combination of whole exome sequencing and genome-wide linkage in autosomal dominant FTLD families excluded for known mutations.
- Trial name
- FTLD-Exome (NCT02363062)
- Where
- France
- Volunteers
- 440 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Asmd, Visceral Type
Biomarkers Of Lung InVolvement In ASMD
The goal of this study is to characterize ASMD patients' breath profile, exhaled breath and condensate as compared to healthy controls to identify specific volatile and non-volatile compounds that reflect inflammatory processes…
- Trial name
- BOLIVIA (NCT05914727)
- Testing
- eNose, Volatile exhaled breath sample, Condensate sample
- Where
- Netherlands
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Eline C. B. Eskes
Alzheimer Disease
Blood Brain Barrier Opening in Alzheimer' Disease
In Alzheimer's disease (AD) an imbalance between the production and clearance of the ß-amyloid peptide is hypothesized as the driving event of the disease.
- Trial name
- BOREAL1 (NCT03119961)
- Testing
- SONOCLOUD®
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Primary Progressive Aphasia, MCI
tDCS Intervention in Primary Progressive Aphasia
Primary progressive aphasia (PPA) is a neurodegenerative disease that affects first and foremost language abilities. Mild cognitive impairment (MCI) is slowly progressive decline in a single domain of cognition (e.g.
- Conditions
- Primary Progressive Aphasia, MCI, FTD
- Trial name
- NCT02606422
- Testing
- Active HD-tDCS plus Speech-Language Therapy
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Corticobasal Syndrome(CBS), Primary Progressive Aphasia(PPA)
Neuroinflammation in FTLD
The goal of this observational study is to investigate the role of neuroinflammation in frontotemporal lobar degeneration (FTLD). The main aims of this study are: 1.
- Conditions
- Corticobasal Syndrome(CBS), Primary Progressive Aphasia(PPA), Progressive Supranuclear Palsy(PSP), Behavioral Variant Frontotemporal Dementia (bvFTD)
- Trial name
- NCT06870838
- Testing
- 7T MRI scan, CSF, Blood withdrawal
- Where
- 2 sites in Netherlands
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Sphingomyelin Lipidosis
Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency
Primary Objective: The primary objective of this phase 2/3 study was to evaluate the efficacy of olipudase alfa (recombinant human acid sphingomyelinase) administered intravenously once every 2 weeks for 52 weeks in adult…
- Trial name
- ASCEND (NCT02004691)
- Testing
- Olipudase alfa
- Where
- 24 sites in United States, Argentina and 15 more
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Genzyme, a Sanofi Company
Primary Progressive Aphasia
The Effects of a Multimodal Approach for the Treatment of PPA
Primary Progressive Aphasia (PPA) is an untreatable neurodegenerative disorder that disrupts language functions. Available therapies are mainly symptomatic and recently attention has been gained by new techniques that allow for…
- Trial name
- ACROSS (NCT04187391)
- Testing
- Active tDCS, Language training, Unstructured cognitive training
- Where
- Italy
- Volunteers
- 47 people
- Sponsor
- IRCCS Centro San Giovanni di Dio Fatebenefratelli
Alzheimer Disease, Cognitive Impairment
The Clinical Impact of the Novel Alzheimer's Blood-based Biomarkers
The goal of this observational study is to determine whether the early adoption of blood-based biomarkers for Alzheimer's disease is associated with an impact on etiological diagnosis, patient's management, emotional impact…
- Conditions
- Alzheimer Disease, Cognitive Impairment, Dementia, Neurodegenerative Diseases
- Trial name
- PLASMAR (NCT06246019)
- Testing
- Early adoption of blood-based biomarkers for Alzheimer's disease
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Hospital del Mar Research Institute (IMIM)
Alzheimer Disease
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease
- Trial name
- NCT05063539
- Testing
- LY3372689
- Where
- 69 sites in United States, Australia and 3 more
- Volunteers
- 327 people
- Sponsor
- Eli Lilly and Company
Dementia-related Psychosis
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
The purpose of this study is to evaluate the efficacy of pimavanserin compared to placebo in preventing relapse of psychotic symptoms in subjects with dementia-related psychosis who responded to 12 weeks of open label…
- Trial name
- NCT03325556
- Testing
- Pimavanserin 34 mg, Pimavanserin 20 mg
- Where
- 83 sites in United States, Bulgaria and 11 more
- Volunteers
- 392 people
- Sponsor
- ACADIA Pharmaceuticals Inc.